Small molecule blocks key glioblastoma driver, raising hopes for new treatment

UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, ...

Lab-grown beef: Novel line of bovine embryonic stem cells shows promise

Researchers in the College of Agriculture, Health and Natural Resources have developed a novel line of bovine embryonic stem ...
Targeted Oncology

Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer

Atebimetinib is an investigational oral deep cyclic inhibitor that targets MEK in the MAPK pathway, which is activated in many solid tumors including pancreatic cancer. Its mechanism of action is ...
IEEE

Precision Oncology: Deciphering Drug Sensitivity Through Multi-Omics Clustering and Machine Learning in Cancer Cell Lines

Abstract: This study combines diverse omics datasets, including Proteomic, Transcriptomic, Genomic, Metabolomic and miRNA profiles from cancer cell lines, with Drug Sensitivity (AUC) data for 285 ...
aad.org

Is red light therapy right for your skin?

Red light is a popular treatment for skin concerns, especially signs of aging like wrinkles, age spots, and sagging skin. People are also using it to treat hair loss. Whether you want to treat your ...
Frontiers

IFNλ1 is a STING-dependent mediator of DNA damage and induces immune activation in lung cancer

Introduction: The importance of the cGAS-STING pathway and type I interferon (IFN) in anti-tumor immunity has been widely studied. However, there is limited knowledge about the role of type III IFNs ...
IEEE

Ultra-Scale ($0.014 \mu ~\mathrm{m}^{2}$) High-Efficient 10A 6T Cfet-Sram Cells Combined Backside Power Deliver Networks and Backside Bit-Lines

Abstract: We design ultra-scale high-efficient 10A 6T CFETSRAM with both backside power deliver networks and backside bit-lines. About Frontside Power Delivery Network (FS-PDN) and Buried Power Rail ...
The American Journal of Managed Care

Exploring CAR T-Cell Therapy Efficacy in Earlier Vs Later Lines of Therapy

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...